Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
|
|
Aridis Pharmaceuticals, Inc. (ARDS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/25/2023 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 08/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/03/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/26/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/21/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/17/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 06/15/2023 |
4
| Patzer Eric (Executive Chairman) has filed a Form 4 on Aridis Pharmaceuticals, Inc.|
Txns:
| Granted 30,000 options
@ $0.16, valued at
$4.8k
Exercised 12,000 restricted stock units
@ $0 |
|
| 06/15/2023 |
4
| HAMILTON JOHN F (Director) has filed a Form 4 on Aridis Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options
@ $0.16, valued at
$2.4k
Exercised 5,000 restricted stock units
@ $0 |
|
| 06/15/2023 |
4
| Truong Vu (CEO and Director) has filed a Form 4 on Aridis Pharmaceuticals, Inc.|
Txns:
| Granted 100,000 options
@ $0.16, valued at
$16k
Exercised 15,000 restricted stock units
@ $0 |
|
| 06/15/2023 |
4
| Windham-Bannister Susan Richards (Director) has filed a Form 4 on Aridis Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options
@ $0.16, valued at
$2.4k
Exercised 5,000 restricted stock units
@ $0 |
|
| 06/15/2023 |
4
| Jafri Hasan (Chief Medical Officer) has filed a Form 4 on Aridis Pharmaceuticals, Inc.|
Txns:
| Granted 25,000 options
@ $0.16, valued at
$4k
Exercised 10,000 restricted stock units
@ $0 |
|
| 06/15/2023 |
4
| KURLAND FRED (CFO) has filed a Form 4 on Aridis Pharmaceuticals, Inc.|
Txns:
| Granted 10,000 options
@ $0.16, valued at
$1.6k
Exercised 4,000 restricted stock units
@ $0 |
|
| 06/09/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 06/08/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/25/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Registrant's ... |
| 05/09/2023 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 05/01/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"ATTACHMENT 1",
"Note Purchase And Loan Restructuring Agreement This Note Purchase and Loan Restructuring Agreement , dated as of April 26, 2023, is entered into by and among Aridis Pharmaceuticals, Inc., a Delaware corporation , Aridis Biopharmaceuticals, LLC, a Delaware limited liability company , Aridis Pharmaceuticals, C.V., a Netherlands partnership , and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns . A. Company and Investor are executing and delivering this Agreement in reliance upon an exemption from securities registration afforded by the Securities Act of 1933, as amended , and the rules and regulations promulgated thereunder by the United States Securities and Exchange Commission . B. ARDS Inc. previously issued to Investor the following promissory n...",
"Exhibit 10.2" |
|
| 04/21/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
8-K
| Resignation/termination of a director |
| 03/31/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/22/2023 |
8-K
| Resignation/termination of a director |
| 03/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/16/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/15/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"VIA ELECTRONIC MAIL",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of March 14, 2023, between Aridis Pharmaceuticals, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purc...",
"Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock" |
|
| 03/13/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in Aridis Pharmaceuticals, Inc. |
| 02/10/2023 |
SC 13G/A
| ASTRAZENECA PLC reports a 3.4% stake in * Aridis Pharmaceuticals, Inc. |
| 12/20/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
|
|
|